AngioDynamics CEO Touts Debt-Free Turnaround, Auryon Share Gains, NanoKnife Launch at Needham Conf [Yahoo! Finance]
AngioDynamics, Inc. (ANGO)
Last angiodynamics, inc. earnings: 4/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.angiodynamics.com/investor-relations
Company Research
Source: Yahoo! Finance
company with no debt , significant cash and a revolver, while its MedTech segment has grown at a ~25% CAGR to nearly half of revenue and could exceed 50% next year. The company's procedural platforms are gaining traction: the Auryon laser moved to the #3 market share in PAD, has a CE mark and is being evaluated for coronary use and possible IVL-like applications, while AngioVac and the new AlphaVac are expanding in the pulmonary embolism (PE) market with growing procedure volumes and supportive clinical data. In oncology, NanoKnife received FDA clearance (Dec 2024) and a CPT I code, sales are growing sequentially, and management pegs the focal prostate cancer TAM at about $1 billion in the U.S. ($2 billion globally) while pursuing awareness, training and potential BPH research. Interested in AngioDynamics, Inc.? Here are five stocks we like better. AngioDynamics (NASDAQ:ANGO) CEO Jim Clemmer used a presentation at Needham & Company's 25th Annual Needham Healthcare Conference t
Show less
Read more
Impact Snapshot
Event Time:
ANGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANGO alerts
High impacting AngioDynamics, Inc. news events
Weekly update
A roundup of the hottest topics
ANGO
News
- AngioDynamics (ANGO) had its price target lowered by Canaccord Genuity Group Inc. from $18.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- AngioDynamics Growing, But With More Noise Than The Street Likes [Seeking Alpha]Seeking Alpha
- AngioDynamics Inc (ANGO) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Amid Financial ... [Yahoo! Finance]Yahoo! Finance
- AngioDynamics Q3 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued ProfitabilityBusiness Wire
ANGO
Earnings
- 4/2/26 - Beat
ANGO
Analyst Actions
- 4/6/26 - Canaccord Genuity
ANGO
Sec Filings
- 4/2/26 - Form 10-Q
- 4/2/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- ANGO's page on the SEC website